CY1107605T1 - Θεραπευτικη αγωγη - Google Patents

Θεραπευτικη αγωγη

Info

Publication number
CY1107605T1
CY1107605T1 CY20071101275T CY071101275T CY1107605T1 CY 1107605 T1 CY1107605 T1 CY 1107605T1 CY 20071101275 T CY20071101275 T CY 20071101275T CY 071101275 T CY071101275 T CY 071101275T CY 1107605 T1 CY1107605 T1 CY 1107605T1
Authority
CY
Cyprus
Prior art keywords
treatment
pharmaceutically acceptable
acceptable salt
egfr
tri
Prior art date
Application number
CY20071101275T
Other languages
English (en)
Inventor
Francis Thomas Boyle
Jon Owen Curwen
Neil James Gallagher
Ursula Joy Hancox
Andrew Mark Hughes
Donna Johnstone
Sian Tomiko Taylor
David William Tonge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1107605T1 publication Critical patent/CY1107605T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Περιγράφεται ένας συνδυασμός, που περιλαμβάνει έναν ανταγωνιστή υποδοχέα ενδοθηλίνης, ή ένα φαρμακευτικώς ανεκτό άλας αυτού, κι έναν EGFR ΤΚΙ, ή ένα φαρμακευτικώς ανεκτό άλας αυτού.
CY20071101275T 2002-10-12 2007-10-08 Θεραπευτικη αγωγη CY1107605T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223854.1A GB0223854D0 (en) 2002-10-12 2002-10-12 Therapeutic treatment
EP03751038A EP1553950B1 (en) 2002-10-12 2003-10-07 Therapeutic treatment

Publications (1)

Publication Number Publication Date
CY1107605T1 true CY1107605T1 (el) 2013-03-13

Family

ID=9945876

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101275T CY1107605T1 (el) 2002-10-12 2007-10-08 Θεραπευτικη αγωγη

Country Status (30)

Country Link
US (1) US20060122180A1 (el)
EP (1) EP1553950B1 (el)
JP (1) JP2006510605A (el)
KR (1) KR20050056238A (el)
CN (1) CN100342853C (el)
AR (1) AR041595A1 (el)
AT (1) ATE369136T1 (el)
AU (1) AU2003269259B2 (el)
BR (1) BR0315140A (el)
CA (1) CA2501959A1 (el)
CY (1) CY1107605T1 (el)
DE (1) DE60315490T2 (el)
DK (1) DK1553950T3 (el)
ES (1) ES2289316T3 (el)
GB (1) GB0223854D0 (el)
HK (1) HK1078784A1 (el)
IS (1) IS2473B (el)
MX (1) MXPA05003808A (el)
MY (1) MY135441A (el)
NO (1) NO20051658L (el)
NZ (1) NZ539137A (el)
PL (1) PL375584A1 (el)
PT (1) PT1553950E (el)
RU (1) RU2005114487A (el)
SA (1) SA04240502B1 (el)
TW (1) TW200412971A (el)
UA (1) UA82492C2 (el)
UY (1) UY28017A1 (el)
WO (1) WO2004035057A1 (el)
ZA (1) ZA200502874B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
EP2209501B1 (en) 2007-10-12 2011-12-14 AstraZeneca AB Zibotentan composition containing mannitol and microcrystalline cellulose
CN102510719B (zh) * 2009-08-10 2015-07-22 得克萨斯大学体系董事会 用与细胞毒性化学治疗剂组合的内皮素受体抑制剂治疗脑转移
KR20200119246A (ko) 2018-01-12 2020-10-19 이엔비 테라퓨틱스, 인크. Etbr 활성화와 관련된 암을 치료하기 위한 중수소화 화합물, 조성물, 및 방법
CN114423425A (zh) * 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
US20240287053A1 (en) 2021-06-22 2024-08-29 Alchemedicine, Inc. Compound, endothelin-a receptor antagonist, and pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
MXPA00010610A (es) * 1998-04-29 2002-07-02 Osi Pharm Inc Mesilato de n-(e-etinilfenilamino)-6,7-bis (2-metoxietoxi)-4-quinazolinamina, anhidro y monohidratado.
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

Also Published As

Publication number Publication date
NO20051658L (no) 2005-05-06
EP1553950B1 (en) 2007-08-08
BR0315140A (pt) 2005-08-16
AR041595A1 (es) 2005-05-26
AU2003269259A1 (en) 2004-05-04
DK1553950T3 (da) 2007-10-15
EP1553950A1 (en) 2005-07-20
ATE369136T1 (de) 2007-08-15
CN100342853C (zh) 2007-10-17
WO2004035057A1 (en) 2004-04-29
IS2473B (is) 2008-12-15
TW200412971A (en) 2004-08-01
AU2003269259B2 (en) 2007-03-15
DE60315490T2 (de) 2008-05-08
MXPA05003808A (es) 2005-06-08
DE60315490D1 (de) 2007-09-20
UA82492C2 (uk) 2008-04-25
NZ539137A (en) 2008-01-31
US20060122180A1 (en) 2006-06-08
UY28017A1 (es) 2004-04-30
PL375584A1 (en) 2005-11-28
KR20050056238A (ko) 2005-06-14
IS7825A (is) 2005-04-26
PT1553950E (pt) 2007-09-26
ZA200502874B (en) 2006-02-22
ES2289316T3 (es) 2008-02-01
CN1703224A (zh) 2005-11-30
SA04240502B1 (ar) 2008-09-14
JP2006510605A (ja) 2006-03-30
HK1078784A1 (en) 2006-03-24
GB0223854D0 (en) 2002-11-20
MY135441A (en) 2008-04-30
CA2501959A1 (en) 2004-04-29
RU2005114487A (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
CY1107605T1 (el) Θεραπευτικη αγωγη
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1116693T1 (el) Συνδυασμος αζελαστινης και κυκλεσονιδης
LU92684I2 (fr) Fidaxomicine ou son sel pharmaceutiquement acceptable
DE60324099D1 (de) Arzneistoffhaltiger tampon
ATE461217T1 (de) Glp-1-verbindungen
NO20044597L (no) Kjemiske forbindelser
ATE328619T1 (de) Chirurgisches absaugsystem
NO20043494L (no) Infeksjonsresistent medisinsk innretning
DK1545662T3 (da) Lægemiddelindgivelsessystem
DE60327090D1 (de) Implantierbare medizinische vorrichtung
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
IS2641B (is) 3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess.
DK1557411T3 (da) N-phenyl-(2r,5s)-dimethylpiperazin-derivat
DK1498147T3 (da) Nedbrydelig biokompatibel blokcopolymer
NO20044448L (no) Nye forbindelser
UY28007A1 (es) Tratamiento terapeutico
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
DE60312992D1 (de) Medizinisches implantat
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
ATE439354T1 (de) Pharmazeutische salze von reboxetin
ITRM20020314A0 (it) Impianto penieno apicale per falloplastica di ingrandimento.
NO20022747L (no) Behandlingsstol